The First, Comprehensive Immunological Model of COVID-19: Implications for Prevention, Diagnosis, and Public Health Measures
暂无分享,去创建一个
[1] V. Lougaris,et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia , 2020, Journal of Allergy and Clinical Immunology.
[2] Mario Plebani,et al. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics , 2020, Clinical chemistry and laboratory medicine.
[3] Shu-Yuan Xiao,et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies , 2020, Modern Pathology.
[4] Dong Yang,et al. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] M. Loosemore,et al. Respiratory health in athletes: facing the COVID-19 challenge , 2020, The Lancet Respiratory Medicine.
[6] R. McIntyre,et al. Tissue plasminogen activator (tPA) treatment for COVID‐19 associated acute respiratory distress syndrome (ARDS): A case series , 2020, Journal of Thrombosis and Haemostasis.
[7] Wayne T. Nicholson,et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. , 2020, The Journal of clinical investigation.
[8] Yan Peng,et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients , 2020, Proceedings of the National Academy of Sciences.
[9] M. Nishimura,et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations , 2020, The Lancet Respiratory Medicine.
[10] S. Merler,et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.
[11] Matthias Klein,et al. Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients , 2020, medRxiv.
[12] A. Vespignani,et al. Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study , 2020, The Lancet Infectious Diseases.
[13] A. Zangrillo,et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis , 2020, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.
[14] Heidi Ledford. How does COVID-19 kill? Uncertainty is hampering doctors’ ability to choose treatments , 2020, Nature.
[15] M. Belingheri,et al. Beyond the assistance: additional exposure situations to COVID-19 for healthcare workers , 2020, Journal of Hospital Infection.
[16] Wei Chen,et al. Extensive Acute Lower Extremity Arterial Thrombosis: A Major Thrombus Formation Caused by COVID-19 , 2020, medRxiv.
[17] Daniel Wrapp,et al. Site-specific analysis of the SARS-CoV-2 glycan shield , 2020, bioRxiv.
[18] Xiang Yao,et al. Knowledge synthesis from 100 million biomedical documents augments the deep expression profiling of coronavirus receptors , 2020, bioRxiv.
[19] J. Dudley,et al. Disparities in Age-Specific Morbidity and Mortality from SARS-CoV-2 in China and the Republic of Korea , 2020, medRxiv.
[20] J. Guarner,et al. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. , 2020, JAMA.
[21] Jing Yuan,et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. , 2020, JAMA.
[22] Jon Brassey,et al. SARS-CoV-2 viral load and the severity of COVID-19 , 2020 .
[23] Guohong Deng,et al. Viral Kinetics and Antibody Responses in Patients with COVID-19 , 2020, medRxiv.
[24] Qi Jin,et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] Beijing China. Prevention,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China , 2020 .
[26] Eric H. Y. Lau,et al. Temporal dynamics in viral shedding and transmissibility of COVID-19 , 2020, Nature Medicine.
[27] G. Wong,et al. SARS-CoV-2 Infection in Children , 2020, The New England journal of medicine.
[28] Lei Liu,et al. Relationship between the ABO Blood Group and the COVID-19 Susceptibility , 2020, medRxiv.
[29] Zhongyi Jiang,et al. Epidemiology of COVID-19 Among Children in China , 2020, Pediatrics.
[30] Arturo Casadevall,et al. The convalescent sera option for containing COVID-19. , 2020, The Journal of clinical investigation.
[31] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[32] Tobias Bleicker,et al. Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster , 2020, medRxiv.
[33] A. Walls,et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.
[34] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[35] Z. Memish,et al. Li Wenliang, a face to the frontline healthcare worker. The first doctor to notify the emergence of the SARS-CoV-2, (COVID-19), outbreak , 2020, International Journal of Infectious Diseases.
[36] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[37] Lei Liu,et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 , 2020, medRxiv.
[38] Dapeng Zhou,et al. Accessible Surface Glycopeptide Motifs on Spike Glycoprotein of 2019-nCoV: Implications on Vaccination and Antibody Therapeutics , 2020 .
[39] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[40] Min Kang,et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients , 2020, The New England journal of medicine.
[41] Dengju Li,et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.
[42] Denisa Bojkova,et al. Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China , 2020, The New England journal of medicine.
[43] D. Heymann,et al. COVID-19: what is next for public health? , 2020, The Lancet.
[44] Christian Drosten,et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group , 2020, bioRxiv.
[45] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[46] N. Linton,et al. Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data , 2020, medRxiv.
[47] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[48] S. Lo,et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.
[49] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[50] Victor M Corman,et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[51] Fang Li,et al. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry , 2019, Journal of Virology.
[52] J. Gildersleeve,et al. Anti-glycan IgM repertoires in newborn human cord blood , 2019, PloS one.
[53] T. Rothstein,et al. Human B-1 Cells and B-1 Cell Antibodies Change With Advancing Age , 2019, Front. Immunol..
[54] A. Walls,et al. Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion , 2019, Cell.
[55] Jack C. Yu,et al. Innate Immunity of Neonates and Infants , 2018, Front. Immunol..
[56] V. Corman,et al. Hosts and Sources of Endemic Human Coronaviruses , 2018, Advances in Virus Research.
[57] J. Pruijt,et al. Truly selective primary IgM deficiency is probably very rare , 2018, Clinical and experimental immunology.
[58] A. Aghamohammadi,et al. Selective IgA Deficiency: Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management , 2017, Scandinavian journal of immunology.
[59] D. Kleinert,et al. The role of complement activation in thrombosis and hemolytic anemias. , 2016, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[60] J. Kearney,et al. Manipulation of the glycan‐specific natural antibody repertoire for immunotherapy , 2016, Immunological reviews.
[61] Saddam M Muthana,et al. Factors Affecting Anti-Glycan IgG and IgM Repertoires in Human Serum , 2016, Scientific Reports.
[62] G. Castaldo,et al. Biological role of mannose binding lectin: From newborns to centenarians. , 2015, Clinica chimica acta; international journal of clinical chemistry.
[63] J. Neuhaus,et al. Elevated soluble thrombomodulin is associated with organ failure and mortality in children with acute respiratory distress syndrome (ARDS): a prospective observational cohort study , 2015, Critical Care.
[64] B. Bertin,et al. Role of mannose-binding lectin in intestinal homeostasis and fungal elimination , 2015, Mucosal Immunology.
[65] K. Koenig. Identify-Isolate-Inform: A Modified Tool for Initial Detection and Management of Middle East Respiratory Syndrome Patients in the Emergency Department , 2015, The western journal of emergency medicine.
[66] L. Cooling. Blood Groups in Infection and Host Susceptibility , 2015, Clinical Microbiology Reviews.
[67] T. Hoffmann,et al. Exercise versus no exercise for the occurrence, severity and duration of acute respiratory infections. , 2015, The Cochrane database of systematic reviews.
[68] W. Liu,et al. Functional polymorphisms of the CCL2 and MBL genes cumulatively increase susceptibility to severe acute respiratory syndrome coronavirus infection , 2015, Journal of Infection.
[69] Saddam M Muthana,et al. Competition between Serum IgG, IgM, and IgA Anti-Glycan Antibodies , 2015, PloS one.
[70] W. Lim,et al. The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis , 2014, The Journal of infectious diseases.
[71] D. Wilkes,et al. Complement system in lung disease. , 2014, American journal of respiratory cell and molecular biology.
[72] Christian Drosten,et al. Serological assays for emerging coronaviruses: Challenges and pitfalls , 2014, Virus Research.
[73] V. Ziaee,et al. Common Sports-Related Infections: A Review on Clinical Pictures, Management and Time to Return to Sports , 2014, Asian journal of sports medicine.
[74] T. Fujita,et al. Structural and Functional Overview of the Lectin Complement Pathway: Its Molecular Basis and Physiological Implication , 2013, Archivum Immunologiae et Therapiae Experimentalis.
[75] J. Vaupel,et al. Activity of mannose‐binding lectin in centenarians , 2012, Aging cell.
[76] N. Baumgarth,et al. B‐1 cells in the bone marrow are a significant source of natural IgM , 2012, European journal of immunology.
[77] P. Bruneval,et al. A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. , 2012, Journal of the American Society of Nephrology : JASN.
[78] J. Otter,et al. Minimum Infective Dose of the Major Human Respiratory and Enteric Viruses Transmitted Through Food and the Environment , 2011, Food and Environmental Virology.
[79] E. Schmidt,et al. High-Dose Mannose-Binding Lectin Therapy for Ebola Virus Infection , 2011, The Journal of infectious diseases.
[80] F. Polack,et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes , 2010, Nature Medicine.
[81] J. Pedrosa,et al. Influenza Infectious Dose May Explain the High Mortality of the Second and Third Wave of 1918–1919 Influenza Pandemic , 2010, PloS one.
[82] J. Sung,et al. Viral Loads and Duration of Viral Shedding in Adult Patients Hospitalized with Influenza , 2009, The Journal of infectious diseases.
[83] D. Eisen. Mannose-Binding Lectin Deficiency and Respiratory Tract Infection , 2009, Journal of Innate Immunity.
[84] Véronique Sébille,et al. Inhibition of the interaction between the SARS-CoV Spike protein and its cellular receptor by anti-histo-blood group antibodies , 2008, Glycobiology.
[85] J. Balzarini. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy , 2007, Nature Reviews Microbiology.
[86] M. Carroll,et al. Natural Antibody and Complement Mediate Neutralization of Influenza Virus in the Absence of Prior Immunity , 2007, Journal of Virology.
[87] C. Franceschi,et al. A Study of Serum Immunoglobulin Levels in Elderly Persons That Provides New Insights into B Cell Immunosenescence , 2006, Annals of the New York Academy of Sciences.
[88] Raymond Tellier,et al. Review of Aerosol Transmission of Influenza A Virus , 2006, Emerging infectious diseases.
[89] N. Klein,et al. Mannose‐binding lectin in innate immunity: past, present and future , 2006, Tissue antigens.
[90] H. Vollmers,et al. Natural IgM antibodies: the orphaned molecules in immune surveillance. , 2006, Advanced drug delivery reviews.
[91] Fuchu He,et al. Association between Mannose-Binding Lectin Gene Polymorphisms and Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection , 2005, The Journal of infectious diseases.
[92] S. Harrison,et al. Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.
[93] H. Gewurz,et al. Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. , 2005, The Journal of general virology.
[94] J. Peiris,et al. Mannose-Binding Lectin in Severe Acute Respiratory Syndrome Coronavirus Infection , 2005, The Journal of infectious diseases.
[95] J. Sung,et al. ABO blood group and susceptibility to severe acute respiratory syndrome. , 2005, JAMA.
[96] Takeshi Kurata,et al. Defense mechanisms against influenza virus infection in the respiratory tract mucosa. , 2004, Japanese journal of infectious diseases.
[97] P. Woo,et al. Viral Loads in Clinical Specimens and SARS Manifestations , 2004, Emerging infectious diseases.
[98] P. Woo,et al. Longitudinal Profile of Immunoglobulin G (IgG), IgM, and IgA Antibodies against the Severe Acute Respiratory Syndrome (SARS) Coronavirus Nucleocapsid Protein in Patients with Pneumonia Due to the SARS Coronavirus , 2004, Clinical Diagnostic Laboratory Immunology.
[99] A. Lo,et al. Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS‐CoV) and its putative receptor, angiotensin‐converting enzyme 2 (ACE2) , 2004, The Journal of pathology.
[100] Qingling Zhang,et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathways , 2004, The Journal of pathology.
[101] G. Tse,et al. Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: an in‐situ hybridization study of fatal cases , 2004, The Journal of pathology.
[102] D. Eisen,et al. Impact of mannose-binding lectin on susceptibility to infectious diseases. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[103] A. Xu,et al. Profile of specific antibodies to the SARS-associated coronavirus. , 2003, The New England journal of medicine.
[104] M. van Herp,et al. SARS and Carlo Urbani. , 2003, The New England journal of medicine.
[105] Christian Drosten,et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.
[106] D. Jack,et al. Mannose-binding lectin is a component of innate mucosal defense against Cryptosporidium parvum in AIDS. , 2000, Gastroenterology.
[107] David C. Nieman,et al. Saliva immunoglobulins in elite women rowers , 2000, European Journal of Applied Physiology.
[108] Wakamiya,et al. Human mannan‐binding lectin inhibits the infection of influenza A virus without complement , 1999, Immunology.
[109] D B Pyne,et al. Salivary IgA levels and infection risk in elite swimmers. , 1999, Medicine and science in sports and exercise.
[110] E. M. Peters,et al. Exercise, Immunology and Upper Respiratory Tract Infections , 1997, International journal of sports medicine.
[111] D. Nieman,et al. Exercise, upper respiratory tract infection, and the immune system. , 1994, Medicine and science in sports and exercise.
[112] G. Stoica,et al. Influence of sex and age on serum immunoglobulin concentrations in healthy subjects. , 1978, Medecine interne.